Cargando…

A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis

BACKGROUND: Patients with cystic fibrosis have to take enzymatic supplements to allow for food digestion. However, an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy (PERT) is inexistent, and lipid content of meals is used as a rough criterion. OBJECTIVE: In this study, an in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo-Lerma, Joaquim, Fornés-Ferrer, Victoria, Peinado, Irene, Heredia, Ana, Ribes-Koninckx, Carmen, Andrés, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386532/
https://www.ncbi.nlm.nih.gov/pubmed/30794618
http://dx.doi.org/10.1371/journal.pone.0212459
_version_ 1783397397763719168
author Calvo-Lerma, Joaquim
Fornés-Ferrer, Victoria
Peinado, Irene
Heredia, Ana
Ribes-Koninckx, Carmen
Andrés, Ana
author_facet Calvo-Lerma, Joaquim
Fornés-Ferrer, Victoria
Peinado, Irene
Heredia, Ana
Ribes-Koninckx, Carmen
Andrés, Ana
author_sort Calvo-Lerma, Joaquim
collection PubMed
description BACKGROUND: Patients with cystic fibrosis have to take enzymatic supplements to allow for food digestion. However, an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy (PERT) is inexistent, and lipid content of meals is used as a rough criterion. OBJECTIVE: In this study, an in vitro digestion model was set up to determine the theoretical optimal dose (TOD) of enzymatic supplement for a selection of foods, which is the dose that allows for maximum lipolysis extent. METHODS: A static in vitro digestion model was applied to simulate digestion of eight foods covering a wide range of lipid contents. First, the dose of the enzymatic supplement was fixed at 2000 lipase units per gram of fat (LU/g fat) using intestinal pH and bile salt concentration as variables. Second, intestinal pH and bile salt concentrations were fixed and the variable was the dose of the enzymatic supplement. Lipolysis extent was determined by measuring the free fatty acids released from initial triglycerides content of foods after digestion. Results in terms of percentage of lipolysis extent were fitted into a linear-mixed segmented model and the deducted equations were used to predict the TOD to reach 90% of lipolysis in every food. In addition, the effect of intestinal pH and bile salt concentration were investigated. RESULTS: The predictive equations obtained for the assessed foods showed that lipolysis was not only dependent on the dose of the enzyme supplement or the lipid content. Moreover, intestinal pH and bile salt concentration had significant effects on lipolysis. Therefore an evidence-based model can be developed taking into account these variables. CONCLUSIONS: Depending on food characteristics, a specific TOD should be assigned to achieve an optimal digestion extent. This work represents a first step towards an evidence-based method for PERT dosing, which will be applied in an in vivo setting to validate its efficacy.
format Online
Article
Text
id pubmed-6386532
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63865322019-03-09 A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis Calvo-Lerma, Joaquim Fornés-Ferrer, Victoria Peinado, Irene Heredia, Ana Ribes-Koninckx, Carmen Andrés, Ana PLoS One Research Article BACKGROUND: Patients with cystic fibrosis have to take enzymatic supplements to allow for food digestion. However, an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy (PERT) is inexistent, and lipid content of meals is used as a rough criterion. OBJECTIVE: In this study, an in vitro digestion model was set up to determine the theoretical optimal dose (TOD) of enzymatic supplement for a selection of foods, which is the dose that allows for maximum lipolysis extent. METHODS: A static in vitro digestion model was applied to simulate digestion of eight foods covering a wide range of lipid contents. First, the dose of the enzymatic supplement was fixed at 2000 lipase units per gram of fat (LU/g fat) using intestinal pH and bile salt concentration as variables. Second, intestinal pH and bile salt concentrations were fixed and the variable was the dose of the enzymatic supplement. Lipolysis extent was determined by measuring the free fatty acids released from initial triglycerides content of foods after digestion. Results in terms of percentage of lipolysis extent were fitted into a linear-mixed segmented model and the deducted equations were used to predict the TOD to reach 90% of lipolysis in every food. In addition, the effect of intestinal pH and bile salt concentration were investigated. RESULTS: The predictive equations obtained for the assessed foods showed that lipolysis was not only dependent on the dose of the enzyme supplement or the lipid content. Moreover, intestinal pH and bile salt concentration had significant effects on lipolysis. Therefore an evidence-based model can be developed taking into account these variables. CONCLUSIONS: Depending on food characteristics, a specific TOD should be assigned to achieve an optimal digestion extent. This work represents a first step towards an evidence-based method for PERT dosing, which will be applied in an in vivo setting to validate its efficacy. Public Library of Science 2019-02-22 /pmc/articles/PMC6386532/ /pubmed/30794618 http://dx.doi.org/10.1371/journal.pone.0212459 Text en © 2019 Calvo-Lerma et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Calvo-Lerma, Joaquim
Fornés-Ferrer, Victoria
Peinado, Irene
Heredia, Ana
Ribes-Koninckx, Carmen
Andrés, Ana
A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis
title A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis
title_full A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis
title_fullStr A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis
title_full_unstemmed A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis
title_short A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis
title_sort first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386532/
https://www.ncbi.nlm.nih.gov/pubmed/30794618
http://dx.doi.org/10.1371/journal.pone.0212459
work_keys_str_mv AT calvolermajoaquim afirstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT fornesferrervictoria afirstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT peinadoirene afirstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT herediaana afirstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT ribeskoninckxcarmen afirstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT andresana afirstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT calvolermajoaquim firstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT fornesferrervictoria firstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT peinadoirene firstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT herediaana firstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT ribeskoninckxcarmen firstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis
AT andresana firstapproachforanevidencebasedinvitrodigestionmethodtoadjustpancreaticenzymereplacementtherapyincysticfibrosis